Please login to the form below

Not currently logged in
Email:
Password:

NICE appoints Andy McKeon to Board

The National Institute for Health and Clinical Excellence has appointed Andy McKeon as a non-executive member of its Board

The National Institute for Health and Clinical Excellence (NICE) has appointed Andy McKeon as a non-executive member of its Board.

McKeon, who is managing director of health at the Audit Commission, will replace Mark Taylor who stepped down in April to take up the role of chair at an NHS Mental Health Trust.

Before joining the Audit Commission, McKeon was director of policy and planning at the Department of Health (DH) with responsibility for setting targets for the reform and improvement of health and social care policy agenda. During his time in post he was responsible for all aspects of the clinical and cost effective use of medicines in the NHS.

Mercy Jeyasingham, MBE, has been reappointed to her non-executive role on NICE's board for a further two-year term. A former member of the Ministerial Advisory Board for the Medicines Control Agency, Mercy is a management consultant and trainer who has held significant senior roles in both the public and voluntary sectors.

The appointments were made by the independent organisation the Appointments Commission which is responsible for appointing chairs and non-executive directors to NHS organisations on behalf of the Secretary of State for Health.

 

25th June 2009

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....
Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...

Infographics